Using Intraoperative Sensing Technology to Evaluate Revision Total Knee Arthroplasty
Launched by ORTHOSENSOR, INC. · Jan 13, 2017
Trial Information
Current as of June 27, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing revision unilateral total knee arthroplasty within the first 5-years of the index procedure
- • Include Male and Female subjects
- • Include subjects 18 years and older
- • Patients should present with idiopathic pain and/or instability/stiffness attributed to aseptic loosening, polyethylene wear or malrotation
- • Patients able to understand study intent, and agree to study participation
- • Patients must be previously implanted with the following cruciate-retaining (CR) or posterior-substituting (PS) total knee systems: Stryker TRIATHLON, Zimmer-Biomet VANGUARD or NEXGEN or Smith and Nephew LEGION or JOURNEY II.
- Exclusion Criteria:
- • No prior revision surgery on operative side
- • Ligament insufficiencies, prior surgeries such as PCL reconstructions, posterolateral reconstructions, osteotomies, tibia plateau fractures
- • Culture positive aspiration indicating infection of the joint
- • ASA class \> III
- • History of drug or alcohol abuse
About Orthosensor, Inc.
Orthosensor, Inc. is a pioneering medical technology company focused on enhancing orthopedic surgery outcomes through innovative sensor technology. With a commitment to improving patient care, Orthosensor develops advanced intraoperative sensors that provide real-time data to surgeons, enabling more precise and informed decision-making during procedures. The company's flagship products aim to optimize joint alignment and stability, ultimately reducing complications and improving recovery times. By leveraging cutting-edge research and development, Orthosensor strives to transform the landscape of orthopedic surgery and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fort Lauderdale, Florida, United States
Patients applied
Trial Officials
William Leone, MD
Principal Investigator
Holy Cross Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials